Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)
Innoviva (INVA) posted Non-Current Deferred Tax Liability of $72.8 million for Q1 2026, up 129.08% on a QoQ basis from $31.8 million in Q4 2025.
Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Innoviva's Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $72.8 million for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (changed N/A YoY) and the FY2025 annual result came in at $31.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was $72.8 million for Q1 2026 at Innoviva, up from $31.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $72.8 million in Q1 2026 and bottomed at $563000.0 in Q4 2023.
- A 5-year average of $20.0 million and a median of $5.6 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability tumbled 90.24% — and 2024, when it dropped 29.4%.
- Innoviva's Non-Current Deferred Tax Liability stood at $5.8 million in 2022, then tumbled by 90.24% to $563000.0 in 2023, then soared by 576.2% to $3.8 million in 2024, then surged by 735.12% to $31.8 million in 2025, then surged by 129.08% to $72.8 million in 2026.
- Business Quant data shows INVA's Non-Current Deferred Tax Liability at $72.8 million in Q1 2026, $31.8 million in Q4 2025, and $3.8 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.83 Mn |
| Mar 31, 2026 | 72.83 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Dec 31, 2025 | 31.79 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 563,000.00 |
| Dec 31, 2023 | 563,000.00 |
| Mar 31, 2023 | 5.39 Mn |
| Mar 31, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.77 Mn |
| Dec 31, 2022 | 5.77 Mn |